Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations.

Watt GF, Scott-Stevens P, Gaohua L.

Drug Discov Today Technol. 2019 Apr;31:69-80. doi: 10.1016/j.ddtec.2019.02.005. Epub 2019 Mar 23. Review.

PMID:
31200862
2.

Extensively hydrolysed infant formulas: Need for aligned definition of peptide size characteristics and standardisation of analytical methods.

Nutten S, Kuslys M, Maynard F, Affolter M, Heine RG, Levin ME, Blackhurst DM, Kirstein F, Kok D, Van der Watt GF, Marais AD.

S Afr Med J. 2018 Oct 26;108(11):887-888. doi: 10.7196/SAMJ.2018.v108i11.13616.

3.

Identification of a single MPV17 nonsense-associated altered splice variant in 24 South African infants with mitochondrial neurohepatopathy.

Meldau S, De Lacy RJ, Riordan GTM, Goddard EA, Pillay K, Fieggen KJ, Marais AD, Van der Watt GF.

Clin Genet. 2018 May;93(5):1093-1096. doi: 10.1111/cge.13208. Epub 2018 Mar 25.

PMID:
29318572
4.

Residual allergenicity of amino acid-based and extensively hydrolysed cow's milk formulas.

Levin ME, Blackhurst DM, Kirstein F, Kok D, Van der Watt GF, Marais AD.

S Afr Med J. 2017 Aug 25;107(9):763-767. doi: 10.7196/SAMJ.2017.v107i9.12137.

PMID:
28875884
5.

Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ.

Allen RA, Brookings DC, Powell MJ, Delgado J, Shuttleworth LK, Merriman M, Fahy IJ, Tewari R, Silva JP, Healy LJ, Davies GCG, Twomey B, Cutler RM, Kotian A, Crosby A, McCluskey G, Watt GF, Payne A.

J Pharmacol Exp Ther. 2017 Jun;361(3):429-440. doi: 10.1124/jpet.116.237347. Epub 2017 Apr 25.

PMID:
28442583
6.

The effectiveness of a multidisciplinary foot care program for children and adolescents with juvenile idiopathic arthritis: an exploratory trial.

Hendry GJ, Watt GF, Brandon M, Friel L, Turner DE, Lorgelly PK, Gardner-Medwin J, Sturrock RD, Woodburn J.

J Rehabil Med. 2013 May;45(5):467-76. doi: 10.2340/16501977-1130.

7.

Cystine urolithiasis in a caracal (Caracal caracal).

Tordiffe AS, van der Watt GF, Reyers F.

J Zoo Wildl Med. 2012 Sep;43(3):649-51.

PMID:
23082535
8.

Hemiatrophy of the spinal cord in a patient with mucopolysaccharidosis type IIIB.

Samia P, Wieselthaler N, van der Watt GF, Wilmshurst JM.

J Child Neurol. 2010 Oct;25(10):1288-91. doi: 10.1177/0883073809360416. Epub 2010 Mar 1.

PMID:
20197271
9.

Prediction of anthropometric foot characteristics in children.

Morrison SC, Durward BR, Watt GF, Donaldson MD.

J Am Podiatr Med Assoc. 2009 Nov-Dec;99(6):497-502.

PMID:
19917735
10.

Protocol for the Foot in Juvenile Idiopathic Arthritis trial (FiJIA): a randomised controlled trial of an integrated foot care programme for foot problems in JIA.

Hendry GJ, Turner DE, McColl J, Lorgelly PK, Sturrock RD, Watt GF, Browne M, Gardner-Medwin J, Friel L, Woodburn J.

J Foot Ankle Res. 2009 Jun 30;2:21. doi: 10.1186/1757-1146-2-21.

11.

A survey of foot problems in juvenile idiopathic arthritis.

Hendry G, Gardner-Medwin J, Watt GF, Woodburn J.

Musculoskeletal Care. 2008 Dec;6(4):221-32. doi: 10.1002/msc.134.

PMID:
18618460
12.

Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists.

Webb A, Johnson A, Fortunato M, Platt A, Crabbe T, Christie MI, Watt GF, Ward SG, Jopling LA.

J Leukoc Biol. 2008 Oct;84(4):1202-12. doi: 10.1189/jlb.0408234. Epub 2008 Jun 27.

PMID:
18586982
13.

Reference change values: how useful are they?

Omar F, van der Watt GF, Pillay TS.

J Clin Pathol. 2008 Apr;61(4):426-7. doi: 10.1136/jcp.2007.054833. Epub 2008 Mar 6. No abstract available.

PMID:
18326016
14.

Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.

Jopling LA, Watt GF, Fisher S, Birch H, Coggon S, Christie MI.

Br J Pharmacol. 2007 Dec;152(8):1260-71. Epub 2007 Nov 5.

15.

The influence of body mass on the temporal parameters of peripubescent gait.

Morrison SC, Durward BR, Watt GF, Donaldson MD.

Gait Posture. 2008 May;27(4):719-21. Epub 2007 Oct 18. No abstract available. Erratum in: Gait Posture. 2009 Nov;30(4):564.

PMID:
17949985
16.

Anthropometric foot structure of peripubescent children with excessive versus normal body mass: a cross-sectional study.

Morrison SC, Durward BR, Watt GF, Donaldson MD.

J Am Podiatr Med Assoc. 2007 Sep-Oct;97(5):366-70.

PMID:
17901340
17.

Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.

McDonald IM, Black JW, Buck IM, Dunstone DJ, Griffin EP, Harper EA, Hull RA, Kalindjian SB, Lilley EJ, Linney ID, Pether MJ, Roberts SP, Shaxted ME, Spencer J, Steel KI, Sykes DA, Walker MK, Watt GF, Wright L, Wright PT, Xun W.

J Med Chem. 2007 Jun 28;50(13):3101-12. Epub 2007 May 31.

PMID:
17536796
18.

Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists.

Buck IM, Black JW, Cooke T, Dunstone DJ, Gaffen JD, Griffin EP, Harper EA, Hull RA, Kalindjian SB, Lilley EJ, Linney ID, Low CM, McDonald IM, Pether MJ, Roberts SP, Shankley NP, Shaxted ME, Steel KI, Sykes DA, Tozer MJ, Watt GF, Walker MK, Wright L, Wright PT.

J Med Chem. 2005 Nov 3;48(22):6803-12.

PMID:
16250639
19.

Prevalence of caseous lymphadenitis and usage of caseous lymphadenitis vaccines in sheep flocks.

Paton MW, Walker SB, Rose IR, Watt GF.

Aust Vet J. 2003 Jan-Feb;81(1-2):91-5.

PMID:
15084020
20.

Very low-density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type Ia (von Gierke disease).

Wierzbicki AS, Watt GF, Lynas J, Winder AF, Wray R.

J Inherit Metab Dis. 2001 Oct;24(5):527-34.

PMID:
11757580
21.

Histamine receptor assays.

Shankley NP, Morton MF, Watt GF.

Curr Protoc Pharmacol. 2001 Nov;Chapter 4:Unit4.17. doi: 10.1002/0471141755.ph0417s14.

PMID:
21959758
22.

Nonpeptide cholecystokinin-2 receptor agonists.

Kalindjian SB, Dunstone DJ, Low CM, Pether MJ, Roberts SP, Tozer MJ, Watt GF, Shankley NP.

J Med Chem. 2001 Apr 12;44(8):1125-33.

PMID:
11312913
23.

Design, synthesis, and structure-activity relationships of novel non-imidazole histamine H(3) receptor antagonists.

Linney ID, Buck IM, Harper EA, Kalindjian SB, Pether MJ, Shankley NP, Watt GF, Wright PT.

J Med Chem. 2000 Jun 15;43(12):2362-70.

PMID:
10882362
24.

From histamine to imidazolylalkyl-sulfonamides: the design of a novel series of histamine H3-receptor antagonists.

Tozer MJ, Harper EA, Kalindjian SB, Pether MJ, Shankley NP, Watt GF.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1825-30. Erratum in: Bioorg Med Chem Lett 1999 Oct 18;9(20):3061.

PMID:
10406649
25.

Analysis of the variation in the action of L-365,260 at CCKB/gastrin receptors in rat, guinea-pig and mouse isolated gastric tissue assays.

Roberts SP, Harper EA, Watt GF, Gerskowitch VP, Hull RA, Shankley NP, Black JW.

Br J Pharmacol. 1996 Aug;118(7):1779-89.

26.

Definition and localization of histamine H2 receptors.

Shankley NP, Watt GF, Black JW.

Eur J Clin Invest. 1995 Mar;25 Suppl 1:12-8. Review. No abstract available.

PMID:
7781671

Supplemental Content

Support Center